This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- HQP1351
- DrugBank Accession Number
- DB16185
- Background
HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for HQP1351 (DB16185)
- Weight
- Average: 532.571
Monoisotopic: 532.219844002 - Chemical Formula
- C29H27F3N6O
- Synonyms
- Hqp-1351 free base
- Hqp1351 free base
- Olverembatinib
- External IDs
- D-824
- GZD-824
- HQP-1351
- HQP1351
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- KV1M7Q3CBP
- CAS number
- 1257628-77-5
- InChI Key
- TZKBVRDEOITLRB-UHFFFAOYSA-N
- InChI
- InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)
- IUPAC Name
- 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide
- SMILES
- CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CC5=C(NN=C5)N=C4)=C(C)C=C3)C=C2)C(F)(F)F)CC1
References
- General References
- Not Available
- External Links
- ChemSpider
- 29395146
- BindingDB
- 50425780
- ChEMBL
- CHEMBL2316582
- ZINC
- ZINC000095594040
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Chronic Phase Chronic Myeloid Leukemia / Olverembatinib / Tyrosine Kinase Inhibitors 1 2 Active Not Recruiting Treatment Accelerated Phase Chronic Myelogenous Leukemia (CML) 1 2 Active Not Recruiting Treatment Chronic Phase Chronic Myeloid Leukemia 2 2 Not Yet Recruiting Treatment Philadelphia-Positive ALL 1 2 Recruiting Treatment Accelerated Phase Chronic Myelogenous Leukemia (CML) / Chronic myeloid leukaemia transformation / Chronic Myeloid Leukemia in Lymphoid Blast Crisis / Chronic Myeloid Leukemia in Myeloid Blast Crisis 1 2 Recruiting Treatment Acute Leukemia / Myeloproliferative Neoplasms (MPNs) 1 2 Recruiting Treatment Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 1 2 Withdrawn Treatment Prophylactic HQP1351 Therapy / Third Generation TKI 1 1 Completed Treatment Chronic Myelogenous Leukemia (CML) 1 1 Completed Treatment Chronic Phase Chronic Myeloid Leukemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00298 mg/mL ALOGPS logP 3.71 ALOGPS logP 4.84 Chemaxon logS -5.2 ALOGPS pKa (Strongest Acidic) 11.08 Chemaxon pKa (Strongest Basic) 7.57 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 77.15 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 142.85 m3·mol-1 Chemaxon Polarizability 55.31 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 15, 2020 18:14 / Updated at December 20, 2020 03:38